506 related articles for article (PubMed ID: 30257597)
1. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis.
Keane S; Geoghegan P; Povoa P; Nseir S; Rodriguez A; Martin-Loeches I
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):839-847. PubMed ID: 30257597
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis.
Demir KK; Butler-Laporte G; Del Corpo O; Ekmekjian T; Sheppard DC; Lee TC; Cheng MP
Mycoses; 2021 Sep; 64(9):1098-1110. PubMed ID: 33894072
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
5. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
[TBL] [Abstract][Full Text] [Related]
6. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodriguez A;
Rev Iberoam Micol; 2014; 31(3):157-75. PubMed ID: 25113990
[TBL] [Abstract][Full Text] [Related]
7. Candidemia and invasive candidiasis in adults: A narrative review.
Antinori S; Milazzo L; Sollima S; Galli M; Corbellino M
Eur J Intern Med; 2016 Oct; 34():21-28. PubMed ID: 27394927
[TBL] [Abstract][Full Text] [Related]
8. Surveillance Study of Epidemiology, Antifungal Susceptibility and Risk Factors of Invasive Candidiasis in Critically ill Patients.
Wang B; Wang Y; Zhang L; Lu F; Zhang M; Xu Y
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704741
[TBL] [Abstract][Full Text] [Related]
9. EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodríguez A;
Rev Esp Quimioter; 2014 Sep; 27(3):196-212. PubMed ID: 25229375
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
Wang H; Xu YC; Hsueh PR
Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
[TBL] [Abstract][Full Text] [Related]
11. Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.
Paredes K; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Guarro J
Rev Iberoam Micol; 2015; 32(1):34-9. PubMed ID: 24594291
[TBL] [Abstract][Full Text] [Related]
12. Candida infections in non-neutropenic children after the neonatal period.
Hacimustafaoglu M; Celebi S
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):923-40. PubMed ID: 21973304
[TBL] [Abstract][Full Text] [Related]
13. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
14. Mind the gaps: challenges in the clinical management of invasive candidiasis in critically ill patients.
Peçanha-Pietrobom PM; Colombo AL
Curr Opin Infect Dis; 2020 Dec; 33(6):441-448. PubMed ID: 33044240
[TBL] [Abstract][Full Text] [Related]
15. [Individualized antifungal therapy in critically ill patients with invasive fungal infection].
Zaragoza R; Maseda E; Pemán J
Rev Iberoam Micol; 2021; 38(2):68-74. PubMed ID: 34301466
[TBL] [Abstract][Full Text] [Related]
16. Caspofungin: a review of its characteristics, activity, and use in intensive care units.
Hashemian SM; Farhadi T; Velayati AA
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1213-1220. PubMed ID: 32662712
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients.
Pea F
Expert Rev Anti Infect Ther; 2013 Oct; 11(10):989-97. PubMed ID: 24093543
[TBL] [Abstract][Full Text] [Related]
18. [Épico project: Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. Grupo Proyecto Épico].
Zaragoza R; Llinares P; Maseda E; Ferrer R; Rodríguez A;
Rev Iberoam Micol; 2013; 30(3 Suppl 1):135-49. PubMed ID: 23764554
[TBL] [Abstract][Full Text] [Related]
19. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
